Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Guselkumab

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    43 result(s) found for: Guselkumab. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2017-002195-13 Sponsor Protocol Number: CNTO1959CRD3001 Start Date*: 2019-06-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2/3, Randomized, Double-blind, Placebo- and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Seve...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) BE (Trial now transitioned) AT (Completed) FR (Trial now transitioned) LT (Completed) CZ (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) GR (Completed) PT (Trial now transitioned) HR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001510-15 Sponsor Protocol Number: CNTO1959UCO2002 Start Date*: 2019-05-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a Randomized, Double-blind, Active-controlled, Parallel-group, Multicenter, Proof-of-concept Clinical Study to Evaluate the Efficacy and Safety of Combination Therapy With Guselkumab and G...
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-001176-38 Sponsor Protocol Number: CNTO1959HDS2001 Start Date*: 2018-10-29
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects with Moderate to Severe Hidradenitis Suppurativa
    Medical condition: Moderate to Severe Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10076650 Acne inversa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) NL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-003206-58 Sponsor Protocol Number: CNTO1959PSO3013 Start Date*: 2019-06-29
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3b, Multicenter, Interventional, Randomized, Placebo controlled Study Investigating the Efficacy and Safety of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis
    Medical condition: Palmoplantar non-Pustular Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-004061-39 Sponsor Protocol Number: CNTO1959PSO4015 Start Date*: 2021-10-22
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 4, Interventional, Single-arm, Open-label Study Evaluating the Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis
    Medical condition: Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Completed) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-004002-25 Sponsor Protocol Number: CNTO1959UCO3001 Start Date*: 2019-10-15
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b/3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) DE (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) NL (Ongoing) BG (Trial now transitioned) AT (Completed) SK (Trial now transitioned) LV (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-003314-39 Sponsor Protocol Number: 78934804CRD2001 Start Date*: 2023-02-21
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gusel...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) CZ (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) AT (Ongoing) PT (Trial now transitioned) BG (Trial now transitioned) IE (Completed) NO (Trial now transitioned) SI (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-006282-37 Sponsor Protocol Number: CNTO1959PBCRD3007 Start Date*: 2023-08-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Multicenter, Randomized, Platform Study of p19 Inhibition of the IL-23 Pathway to Establish Efficacy in Pediatric Crohn’s Disease
    Medical condition: Moderately to Severely Active Crohn’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) AT (Trial now transitioned) PT (Trial now transitioned) ES (Ongoing) NL (Trial now transitioned) PL (Trial now transitioned) Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2021-000491-10 Sponsor Protocol Number: CNTO1959CRD3005 Start Date*: 2022-06-22
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Randomized, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab in Participants with Fistulizing, Perianal Crohn’s Disease
    Medical condition: Fistulizing perianal Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10075465 Fistulizing Crohn's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000719-15 Sponsor Protocol Number: CNTO1959PSO3001 Start Date*: 2014-10-24
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-005503-40 Sponsor Protocol Number: CNTO1275JPA3001 Start Date*: 2022-11-15
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Multicenter, Open-label Study to Evaluate the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of Subcutaneously Administered Ustekinumab or Guselkumab in Pediatric Participants Wit...
    Medical condition: Juvenile Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10076674 Juvenile psoriatic arthritis PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Trial now transitioned) IT (Trial now transitioned) Outside EU/EEA FR (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-005528-39 Sponsor Protocol Number: 78934804UCO2001 Start Date*: 2023-02-16
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gusel...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) HU (Ongoing) CZ (Trial now transitioned) NL (Trial now transitioned) SK (Trial now transitioned) AT (Trial now transitioned) BG (Trial now transitioned) FR (Trial now transitioned) NO (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) PT (Trial now transitioned) SI (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-000720-18 Sponsor Protocol Number: CNTO1959PSO3002 Start Date*: 2015-02-11
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects with Moderate to Seve...
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2018-002978-52 Sponsor Protocol Number: CNTO1959HDS2002 Start Date*: 2019-07-16
    Sponsor Name:Universitair Medisch Centrum Groningen
    Full Title: Guselkumab for hidradenitis suppurativa, a mode of action study.
    Medical condition: Hidradenitis suppurativa
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002389-33 Sponsor Protocol Number: CNTO1959CRD3007 Start Date*: 2023-04-07
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants with Crohn’s Disease After Surgical Resection
    Medical condition: Crohn’s Disease After Surgical Resection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001238-16 Sponsor Protocol Number: CNTO1959PSO3012 Start Date*: 2019-01-03
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3b, Randomized, Double-blind, Active-controlled, Multicenter Study to Evaluate Further Therapeutic Strategies with Guselkumab in Patients with Moderate-to-Severe Plaque-Type Psoriasis
    Medical condition: Moderate to Severe Plaque Type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-006165-11 Sponsor Protocol Number: CNTO1959CRD3004 Start Date*: 2022-04-19
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately t...
    Medical condition: Moderately to Severely Active Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) LT (Trial now transitioned) NL (Prematurely Ended) IT (Trial now transitioned) PL (Trial now transitioned) DE (Trial now transitioned) SK (Trial now transitioned) BE (Completed) NO (Completed) DK (Prematurely Ended) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-000365-41 Sponsor Protocol Number: CNTO1959UCO3004 Start Date*: 2023-04-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Mode...
    Medical condition: Moderately to Severely Active Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002012-31 Sponsor Protocol Number: CNTO1959PSA2003 Start Date*: 2021-10-08
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a, Multicenter, Randomized, Double-blind Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab and Golimumab Combination Therapy in Participants with Active Ps...
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed) DK (Completed) HU (Completed) FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-003697-17 Sponsor Protocol Number: CNTO1959PSA2001 Start Date*: 2015-04-22
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab in the Treatment of Subjects With Active Psoriatic Arthritis
    Medical condition: Active Psoriatic Arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004859 10037160 Psoriatic arthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:34:57 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA